-
Invasive pneumococcal disease (IPD)
is a leading cause of serious clinical
infections including pneumonia, bacteremia
without focus and meningitis.1
-
In adults, observational and
case-control studies have shown that
pneumococcal vaccination is efficacious against
IPD.4
-
In children, randomised
controlled trials have found that pneumococcal
conjugate vaccination is effective in reducing
the incidence of IPD and the incidence of X-ray
confirmed pneumonia.5
-
The role of pneumococcal
vaccination for people with asthma is unclear;
there is not enough evidence to warrant a
recommendation of routine vaccination for all
people with asthma.27
-
There is no direct evidence of
efficacy in preventing pneumococcal
exacerbations of COPD.7 However, vaccination of
people with COPD is recommended.1,7
-
Vaccination with 23vPPV is
recommended for immunocompetent persons aged 5
years and older who are at risk of IPD due to
chronic illness, including chronic cardiac
disease and diabetes.1
-
Children who are at increased
risk of IPD, including those with diabetes or
cardiac disease leading to cyanosis or cardiac
failure, should receive a fourth booster dose of
7vPCV at 12 months of age and a booster dose of
23vPPV at 4-5 years of age.1
